![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Under the Agreement, Shortwave will be the exclusive commercial partner in an investigator-initiated, open-label, phase II study of the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa (the "Trial").
Lead Product(s): Psilocybine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: The Sheba Center for Eating Disorders
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 15, 2022